Trends in Molecular Medicine, Journal Year: 2025, Volume and Issue: unknown
Published: June 1, 2025
Language: Английский
Trends in Molecular Medicine, Journal Year: 2025, Volume and Issue: unknown
Published: June 1, 2025
Language: Английский
Archives of Toxicology, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 10, 2025
Language: Английский
Citations
2Journal of Hazardous Materials, Journal Year: 2025, Volume and Issue: 489, P. 137605 - 137605
Published: Feb. 13, 2025
Language: Английский
Citations
2International Immunopharmacology, Journal Year: 2025, Volume and Issue: 152, P. 114375 - 114375
Published: March 4, 2025
Language: Английский
Citations
0Advances in Clinical Medicine, Journal Year: 2025, Volume and Issue: 15(04), P. 518 - 530
Published: Jan. 1, 2025
Language: Английский
Citations
0Comprehensive physiology, Journal Year: 2025, Volume and Issue: 15(3)
Published: May 1, 2025
Pulmonary fibrosis (PF) is a chronic, progressive fibrotic interstitial lung disease characterized by high incidence and mortality rate, which encompasses features, such as diffuse alveolar inflammation, invasive fibroblast activation, uncontrolled extracellular matrix (ECM) deposition. Beyond the local pathological processes, PF can be better understood in light of interorgan communication networks that are involved its progression. Notably, pulmonary inflammation affect cardiovascular, renal, hepatic, neural functions, highlighting importance understanding these systemic interactions. Posttranslational modifications play crucial role regulating protein function, localization, stability, activity. Specifically, ubiquitination induced various stimuli, involving range ubiquitin-modifying enzymes substrates. In this review, we provide an overview how E3 ubiquitin ligases deubiquitinating (DUBs) modulate through several signaling pathways, TGF-β, Wnt, metabolic activity, aging, ferroptosis, endoplasmic reticulum stress, inflammatory responses. This perspective includes ubiquitin-proteasome systems communication, affecting progression related conditions. Additionally, also summarize currently available therapeutic compounds targeting ubiquitination-related or substrates for treatment PF. Understanding interplay between may pave way novel strategies.
Language: Английский
Citations
0Journal of Translational Medicine, Journal Year: 2025, Volume and Issue: 23(1)
Published: May 8, 2025
Pulmonary fibrosis (PF) is a chronic, progressive interstitial lung disease characterized by excessive deposition of extracellular matrix (ECM) and abnormal fibroblast proliferation, which mainly caused air pollution, smoking, aging, occupational exposure, environmental pollutants microbial infections. Although antifibrotic agents such as pirfenidone nintedanib, approved the United States (US) Food Drug Administration (FDA), can slow decline in function progression, their side effects delivery inefficiency limit overall prognosis PF. Therefore, there an urgent need to develop effective therapeutic targets approaches for PF clinical settings. This review provides overview pathogenic mechanisms, drug targeting signaling pathways, promising strategies treating
Language: Английский
Citations
0Trends in Molecular Medicine, Journal Year: 2025, Volume and Issue: unknown
Published: June 1, 2025
Language: Английский
Citations
0